Literature DB >> 23313194

The role of c-FLIP in cisplatin resistance of human bladder cancer cells.

Sangchul Lee1, Cheol Yong Yoon, Seok-Soo Byun, Eunsik Lee, Sang Eun Lee.   

Abstract

PURPOSE: We investigated the mechanisms underlying cisplatin resistance in human bladder cancer cells to provide novel molecular targets for the treatment of cisplatin resistant bladder cancer.
MATERIALS AND METHODS: The differential gene expression of cisplatin sensitive (T24) and resistant (T24R2) human bladder cancer cell lines was analyzed and validated by microarray and Western blot analysis. Changes in cisplatin sensitivity by c-FLIP knockdown and related mechanisms in T24R2 cells were assessed using the Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, Maryland) and Western blot. siRNA oligonucleotides that specifically target c-FLIP were prepared and siRNA transfection was done.
RESULTS: Microarray analysis revealed that the expression of 1,086 and 322 genes showed more than twofold and fourfold changes in the T24R2 and T24 cell lines, respectively. Especially genes involved in the c-FLIP related death receptor apoptosis pathway, including caspase 2 and 9, NF-kB, BID, c-FLIP, XIAP, and cIAP1 and 2, showed differential expression in the 2 cell lines. Western blot demonstrated complete cisplatin mediated suppression of c-FLIP expression in T24 cells but no change in c-FLIP expression was observed in T24R2 cells after cisplatin treatment in the same dose range. Suppression of c-FLIP expression in T24R2 cells by siRNA transfection rendered these cells significantly more sensitive to cisplatin treatment than untransfected T24R2 cells (p <0.05).
CONCLUSIONS: Results reveal that c-FLIP has an important role in the cisplatin resistance of human bladder cancer cells and c-FLIP modulation may at least partially reverse cisplatin resistance in bladder cancer cells.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313194     DOI: 10.1016/j.juro.2013.01.003

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

Authors:  Daniel B Longley; Victoria Coyle; Jennifer Ferris; Margarita Espona-Fiedler; Claudia Hamilton; Caitriona Holohan; Nyree Crawford; Alex J McIntyre; Jamie Z Roberts; Mark Wappett; Simon S McDade
Journal:  Cell Death Discov       Date:  2020-07-21

2.  Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.

Authors:  Sangchul Lee; Kwangtaek Kim; Jin-Nyoung Ho; Hyunjin Jin; Seok-Soo Byun; Eunsik Lee
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 3.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

4.  Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL.

Authors:  Jichun Sun; Hongwu Luo; Wanpin Nie; Xundi Xu; Xiongying Miao; Feizhou Huang; Haiyan Wu; Xiaoxin Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Hyperforin Induces Apoptosis Through Extrinsic/Intrinsic Pathways and Inhibits NF-ĸB-modulated Survival and Invasion Potential in Bladder Cancer.

Authors:  Yu-Chang Liu; Kuang-Hsuan Lin; Jung-Hung Hsieh; Jing-Gung Chung; Zhao-Lin Tan; Fei-Ting Hsu; Chih-Hung Chiang
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

6.  Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.

Authors:  Lata Chauhan; Gregory D Jenkins; Neha Bhise; Tanya Feldberg; Taraswi Mitra-Ghosh; Brooke L Fridley; Jatinder K Lamba
Journal:  BMC Genomics       Date:  2015-06-30       Impact factor: 3.969

7.  Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.

Authors:  Sung Han Kim; Jin-Nyoung Ho; Hyunjin Jin; Sang Chul Lee; Sang Eun Lee; Sung-Kyu Hong; Jeong Woo Lee; Eun-Sik Lee; Seok-Soo Byun
Journal:  Investig Clin Urol       Date:  2016-01-11

Review 8.  Cancer drug resistance: redox resetting renders a way.

Authors:  Yuan Liu; Qifu Li; Li Zhou; Na Xie; Edouard C Nice; Haiyuan Zhang; Canhua Huang; Yunlong Lei
Journal:  Oncotarget       Date:  2016-07-05

9.  PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.

Authors:  Khuloud Bajbouj; Rakhee K Ramakrishnan; Maha Saber-Ayad; Hany A Omar; Narjes Saheb Sharif-Askari; Jasmin Shafarin; Adel B Elmoselhi; Ahmed Ihmaid; Suhib AlHaj Ali; Abdulla Alalool; Reem Abdullah; Qutayba Hamid
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.

Authors:  P Godwin; A M Baird; S Heavey; M P Barr; K J O'Byrne; K Gately
Journal:  Front Oncol       Date:  2013-05-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.